Results 101 to 110 of about 20,522 (204)
Ezetimibe: New perspectives in lipid lowering treatment [PDF]
Therapeutic goals for lipid lowering treatment in the prevention of ischemic heart disease are often not reached in clinical practice. Even the highest doses of statins do not guarantee good control of hypercholesterolemia in all patients. Therefore, new
Jankowski, Piotr; 1st Clinic of Cardiology University Hospital, Cracow, Poland +2 more
core
The role of ezetimibe in the treatment of cardiovascular disease
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Despite the success of treatment of CVD with statin therapy, a number of patients remain at high risk for CVD.
Virani, Salim S. +3 more
core +1 more source
Abstract Supplement HIV Glasgow 8–11 November 2026, Glasgow, UK/Virtual
Journal of the International AIDS Society, Volume 29, Issue S6, November 2026.
wiley +1 more source
Immunomodulatory_Roles_of_Statin/Ezetimibe
[Title of corresponding article]Distinct Effects of Rosuvastatin and Rosuvastatin/Ezetimibe on Senescence Markers of CD8+ T cells in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial[Author list]Sang-Hyeon Ju1†, Thi Linh Nguyen2 ...
Ju, S (via Mendeley Data), Ju, Sanghyeon
core +1 more source
Ezetimibe and the risk of new-onset type 2 diabetes: a systematic review and meta-analysis
Background Statins reduce cardiovascular risk but may increase new-onset type 2 diabetes mellitus (NO-T2DM). Ezetimibe, a cholesterol absorption inhibitor, is often added to statins to improve lipid control, yet its impact on NO-T2DM remains uncertain ...
Areej S. Albawa’neh +6 more
doaj +1 more source
Effect of ezetimibe on incretin secretion in response to the intestinal absorption of a mixed meal
Ezetimibe is a potent inhibitor of cholesterol absorption by enterocytes. Although ezetimibe minimally affects the absorption of triglyceride, it is unknown whether ezetimibe affects the secretion of the incretin hormones glucose-dependent insulinotropic
Yong Ji +8 more
core +1 more source
Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes [PDF]
Ezetimibe selectively inhibits dietary and biliary cholesterol absorption and reduces serum cholesterol levels when administered alone (monotherapy) and along with common lipid-regulating agents (combination therapy).
キシモト, ミヤコ +11 more
core
Serious drug-induced liver disease secondary to ezetimibe
Ezetimibe is the first member of a new family of lipid-lowering drugs that inhibits uptake of dietary and biliary cholesterol. It was approved by the FDA in 2002 for hypercholesterolemia alone or in combination with statins.
Girbau, Anna +4 more
core +1 more source

